Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice.
Immune checkpoint inhibitors targeting PD-1 or PD-L1 represent a standard treatment option for patients with advanced non-small-cell lung cancer. However, a substantial proportion of patients will not benefit from these treatments, and robust biomarkers are required to help clinicians select patients who are most likely to benefit. Here, we discuss the available evidence on the utility of clinical characteristics in the selection of patients with advanced non-small-cell lung cancer as potential candidates for single-agent anti-PD-1/PD-L1 therapy, and provide practical guidance to clinicians on identifying those patients who are most likely to benefit. Recommendations on the use of immune checkpoint inhibitor in clinically challenging populations are also provided.
['Califano|Raffaele|R|', 'Lal|Rohit|R|', 'Lewanski|Conrad|C|', 'Nicolson|Marianne C|MC|', 'Ottensmeier|Christian H|CH|', 'Popat|Sanjay|S|', 'Hodgson|Matthew|M|', 'Postmus|Pieter E|PE|']
D000367:Age Factors D000074322:Antineoplastic Agents, Immunological D060890:B7-H1 Antigen D014408:Biomarkers, Tumor D002289:Carcinoma, Non-Small-Cell Lung D002986:Clinical Trials as Topic D018450:Disease Progression D006801:Humans D008175:Lung Neoplasms D058990:Molecular Targeted Therapy D009154:Mutation D009362:Neoplasm Metastasis D009367:Neoplasm Staging D018579:Patient Selection D017410:Practice Guidelines as Topic D061026:Programmed Cell Death 1 Receptor D012307:Risk Factors D016896:Treatment Outcome
patient selection non-small-cell lung cancer atezolizumab immune checkpoint blockade nivolumab pembrolizumab